Connect with us

/home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
">
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

Warning: Attempt to read property "cat_name" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

Attracting Investments in European HealthTech Leaders at the first HTID Conference in Paris – on June 24-25th

Published

on

Reading Time: 2 minutes

PARIS–(BUSINESS WIRE)–lt;a href=”https://twitter.com/hashtag/HTID_Paris?src=hash” target=”_blank”gt;#HTID_Parislt;/agt;–The first edition of the HealthTech Investor Days (HTID)
will take place in Paris on June 24th and 25th
2019. This new forum will help 100 late-stage European HealthTech
companies secure the development of new medicines and therapeutic
solutions. Launched by France Biotech with the support of the European
health innovation ecosystem, HTID will facilitate one-on-one meetings
between European health entrepreneurs, international investors and major
pharmaceutical companies. The two-day event will also feature a dozen
plenary meetings on global issues in health innovation.

Europe is a major player in medicine of the future thanks to the
excellence of its scientific research and the growing number of
innovative HealthTech companies. It is home to 3,000 biotechs and 27,000
medtechs according to European sources EuropaBio and Medtech Europe.

Europe’s potential in health innovation is hampered by the structural
weakness in funding for the sector which requires large capital
investments and long-term financing. The development of a new drug from
benchside research to the market takes ten to fifteen years on average.
For medical devices, the development process usually lasts three to
seven years.

In the past two years, investment in HealthTech companies around the
world has been rising sharply. However, Europe has benefited only
partially from this trend. In 2017, the global amount of funds raised in
the HealthTech sector in Europe (via venture capital and IPOs) reached €
6.2 billion (source: EY). This represents less than a third of the funds
raised in the United States alone during the same period (€ 19.8
billion). In 2018, the European investment deficit increased further
with a total of 5.8 billion euros funds raised (down 6.5% compared to
2017). Meanwhile, 27 billion euros (+ 36.3%) were invested in HealthTech
in the United States. This means that American health innovation now
attracts five times more investment than European health innovation.

HTID is a response to this crucial need for financing and support by the
industry. The event will take place on an annual basis to help overcome
this lack of investment in the European HealthTech sector.

Contacts

Press contacts:
ALIZE RP:
Caroline Carmagnol
[email protected]


Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493

Warning: Attempt to read property "cat_ID" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493

Cannabis

Sannabis, Inc. (OTC: USPS) Announces First Shipment of Cannabis Essential Oil from Colombia to U.S. to Fill First Order, as the DEA Re-Classifies Marijuana from Schedule I to Schedule III

Published

on

Continue Reading

Humboldt

Humboldt Seed Company partners with Apollo Green to bring California cannabis genetics to the global marketplace

Published

on

humboldt-seed-company-partners-with-apollo-green-to-bring-california-cannabis-genetics-to-the-global-marketplace

Apollo Green to distribute Humboldt Seed Company clonal cannabis genetics to Germany, Portugal and Australia

SAN FRANCISCO, April 30, 2024 /PRNewswire/ — Humboldt Seed Company (HSC), California’s leading cannabis seed producer, has announced a partnership with Canadian-based Apollo Green to make eight breeder cuts available to researchers, licensed commercial cultivators and home growers in legal markets worldwide. This first-to-market clonal genetics release is a significant milestone and will expand access to distinctive, high-quality cannabis genetics in both established and emerging global markets including Germany, Portugal and Australia.

The curated, breeder-verified selection includes pioneering triploid genetics, such as OG Triploid and Donutz Triploid alongside the legendary cult classic Blueberry Muffin. Also available are All Gas OG with a THC content of 21% and four high-THC strains in the 30-35% range: Golden Sands, Guzzlerz, Jelly Donutz and Orange Creampop. These selections represent the top .01% from HSC’s extensive California pheno-hunting program.

Exports will begin in May under Apollo Green’s Canadian federal cannabis license. All shipments have Canadian phytosanitary certification, ensuring plants have been inspected, and are clean and free of pests.

“Access for all to quality genetics has been our core focus since the beginning,” said HSC Co-founder and Chief Science Officer, Benjamin Lind. “Our science-based approach to breeding aligns perfectly with Apollo Green’s high standards and we are excited to be able to extend these hand-selected cuts to a wider audience, especially at this pivotal time where we’re seeing positive regulatory changes globally.”

Oisin Tierney, Apollo Green Director of Business Development, said, “California has long been recognized for setting industry standards, and we are proud to play a role in bringing these esteemed genetics to cultivators worldwide. The triploids are especially noteworthy in terms of the unprecedented potential for enhanced plant vigor, higher yields, shorter flowering times and superior returns for solventless extraction.”

About Humboldt Seed Company

Established in 2001, Humboldt Seed Company is a Northern California heritage brand providing quality cannabis genetics to commercial cultivators and home growers in legalized states across the U.S. and international markets including Spain, Canada, Jamaica, South Africa, Colombia, France, Portugal, Greece, the UK, Malta and Thailand. With a focus on environmental and social justice, they combine traditional breeding and modern scientific practices in their strain development program. They have served the cannabis community for over two decades.

For more information visit https://humboldtseedcompany.com/.

About Apollo Green

Licensed since 2019, Apollo Green is Canada’s leader in cannabis genetics. The company’s mission is to provide an ever-growing bank of seeds and clones to medical patients and recreational consumers. Apollo Green provides clean, trusted cannabis seeds and clones, which are backed by the foremost tissue culture technology to reduce risks, costs and time-to-market for licensed producers around the world. Apollo Green is passionate about cannabis genetics. 

For more information visit https://apollogreen.com/.

Media contact
Jaana Prall
[email protected] 

Logo – https://mma.prnewswire.com/media/2328955/Humboldt_Seed_Company_Logo.jpg 

Cision View original content:https://www.prnewswire.co.uk/news-releases/humboldt-seed-company-partners-with-apollo-green-to-bring-california-cannabis-genetics-to-the-global-marketplace-302131618.html

Continue Reading

Cannabis

Technological Advancements in Breathalyzers Drive Market Growth and Enhance Road Safety

Published

on

Continue Reading
Advertisement

Latest news

Trending on Grassnews

GrassNews.net: Your premier portal for the latest developments in the cannabis industry. We provide timely news, insightful analysis, and in-depth features on everything from legislation changes and business trends, to scientific research and lifestyle topics. Stay informed and navigate the rapidly evolving cannabis landscape with GrassNews.net..

Contact us: [email protected]

Editorial / PR Submissions

Copyright © 2007 - 2024 Hipther Agency. Registered in Romania under Proshirt SRL, Company number: 2134306, EU VAT ID: RO21343605. Office address: Blvd. 1 Decembrie 1918 nr.5, Targu Mures, Romania